Abstract

The Developmental Research Program is designed to develop innovative prostate cancer translationalresearch. As such, it supports novel translational research projects or research projects with definite potentialto provide a scientific base for future translational research. This program is of great importance to thesuccess of the Prostate SPORE because it enables a proactive stance in identifying and supporting innovativehypothesis-driven research. The availability of this support also provides a stimulus for creativity in theresearch community, a vehicle for encouraging the interaction of basic scientists and translationalinvestigators, and an opportunity for expanding the research spectrum of the SPORE by pursuing new leadsbased on discoveries and/or opportunities that arise. We have requested $100,000 in the application tosupport this program. In addition Mayo will provide an additional $50,000 for the Developmental ResearchProgram (See letter of commitment from Dr. Hugh Smith, CEO and Chair of the Board of Governors of MayoClinic, Rochester, and Vice President of the Mayo Foundation). Thus, we plan to commit a total of $150,000 tothe Developmental Research Program.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA091956-08
Application #
7729587
Study Section
Special Emphasis Panel (ZCA1-GRB-I (M1))
Project Start
2008-09-11
Project End
2011-08-31
Budget Start
2008-09-11
Budget End
2009-08-31
Support Year
8
Fiscal Year
2008
Total Cost
$89,567
Indirect Cost

  Institution

Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905

  Publications

Guerrico, Anatilde Gonzalez; Hillman, David; Karnes, Jeffery et al. (2017) Roles of kallikrein-2 biomarkers (free-hK2 and pro-hK2) for predicting prostate cancer progression-free survival. J Circ Biomark 6:1849454417720151
Hearn, Jason W D; AbuAli, Ghada; Reichard, Chad A et al. (2016) HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. Lancet Oncol 17:1435-1444
Spratt, Daniel E; Evans, Michael J; Davis, Brian J et al. (2015) Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation. Cancer Res 75:4688-96
Lu, Ji; Lonergan, Peter E; Nacusi, Lucas P et al. (2015) The cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cells. J Urol 193:690-8
Urban, Matthew W; Wang, Chenyi; Alizad, Azra et al. (2015) Complex background suppression for vibro-acoustography images. Ultrasonics 56:456-72
Cooperberg, Matthew R; Davicioni, Elai; Crisan, Anamaria et al. (2015) Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol 67:326-33
Alshalalfa, Mohammed; Crisan, Anamaria; Vergara, Ismael A et al. (2015) Clinical and genomic analysis of metastatic prostate cancer progression with a background of postoperative biochemical recurrence. BJU Int 116:556-67
Loeb, Stacy; Sanda, Martin G; Broyles, Dennis L et al. (2015) The prostate health index selectively identifies clinically significant prostate cancer. J Urol 193:1163-9
Ding, Liya; Chen, Shuai; Liu, Ping et al. (2014) CBP loss cooperates with PTEN haploinsufficiency to drive prostate cancer: implications for epigenetic therapy. Cancer Res 74:2050-61
Mehrmohammadi, Mohammad; Alizad, Azra; Kinnick, Randall R et al. (2014) Feasibility of vibro-acoustography with a quasi-2D ultrasound array transducer for detection and localizing of permanent prostate brachytherapy seeds: a pilot ex vivo study. Med Phys 41:092902

Showing the most recent 10 out of 206 publications